2315 — Biocytogen Pharmaceuticals Beijing Co Income Statement
0.000.00%
Last trade - 00:00
- HK$2.96bn
- HK$3.11bn
- CNY716.91m
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 254 | 355 | 534 | 717 |
Cost of Revenue | ||||
Gross Profit | 167 | 247 | 392 | 506 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 612 | 860 | 1,064 | 987 |
Operating Profit | -358 | -506 | -530 | -270 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -477 | -546 | -601 | -380 |
Provision for Income Taxes | ||||
Net Income After Taxes | -477 | -546 | -602 | -383 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | -428 | -546 | -602 | -383 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -428 | -546 | -602 | -383 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -1.12 | -1.4 | -1.63 | -0.988 |